☆ 4.8 Letter

Detection of Drug-Resistant Tuberculosis by Xpert MTB/RIF in Swaziland

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Journal

NEW ENGLAND JOURNAL OF MEDICINE

Volume 372, Issue 12, Pages 1181-1182

Publisher

MASSACHUSETTS MEDICAL SOC

DOI: 10.1056/NEJMc1413930

Keywords

-

Categories

Medicine, General & Internal

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Review Medicine, General & Internal

Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults

Mikashmi Kohli, Ian Schiller, Nandini Dendukuri, Mandy Yao, Keertan Dheda, Claudia M. Denkinger, Samuel G. Schumacher, Karen R. Steingart

Summary: Xpert Ultra and Xpert MTB/RIF are effective tools for diagnosing extrapulmonary tuberculosis, particularly for detecting rifampicin resistance cases. Xpert Ultra has higher sensitivity and lower specificity compared to Xpert MTB/RIF in diagnosing tuberculous meningitis, while both tests have similar sensitivity and specificity in detecting rifampicin resistance. Future research should address the limitations associated with using culture as a reference standard in paucibacillary specimens.

COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2021)

Add to Collection

Article Microbiology

Comparison of Analytical Sensitivity (Limit of Detection) of Xpert MTB/RIF and Xpert MTB/RIF Ultra for Non-Sputum Specimens

Marisa C. C. Nielsen, Paula Clarner, Ruchi Paroha, Sunhee Lee, Phyu M. M. Thwe, Ping Ren

Summary: Tuberculosis (TB) is a major public health threat and remains a leading cause of death worldwide. The Cepheid Xpert (R) MTB/RIF tests are widely accepted for TB diagnosis, but their sensitivity on non-sputum samples has not been determined. This study systematically evaluated the sensitivity of US-IVD and Ultra tests on different sample types including CSF, tissue, and BAL. The Ultra test showed better sensitivity than US-IVD across all sample types, providing a foundation for early detection of pulmonary and extrapulmonary TB and potentially improving TB case detection rates.

PATHOGENS (2023)

Add to Collection

Article Infectious Diseases

Xpert MTB/RIF Ultra outperformed the Xpert assay in tuberculosis lymphadenitis diagnosis: a prospective head-to-head cohort study

Xia Yu, Tingting Zhang, Yaoyao Kong, Fen Wang, Lingling Dong, Ming Han, Hairong Huang

Summary: Xpert-Ultra demonstrates significantly higher sensitivity in the detection of tuberculosis lymphadenitis, particularly in lymph node tissue.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2022)

Add to Collection

Article Microbiology

To Test or Not? Xpert MTB/RIF as an Alternative to Smear Microscopy to Guide Line Probe Assay Testing for Drug-Resistant Tuberculosis

S. Pillay, M. de Vos, H. Sohn, Y. Ghebrekristos, T. Dolby, R. M. Warren, G. Theron

Summary: Xpert MTB/RIF (Xpert) revolutionized TB diagnosis and its quantitative information can identify a subset of smear-negative specimens, allowing laboratories to perform drug susceptibility testing on them.

JOURNAL OF CLINICAL MICROBIOLOGY (2023)

Add to Collection

Article Microbiology

Diagnostic Performance of Xpert MTB/RIF Ultra Compared with Predecessor Test, Xpert MTB/RIF, in a Low TB Incidence Setting: a Retrospective Service Evaluation

Mary Mansfield, Anne Marie McLaughlin, Emma Roycroft, Lorraine Montgomery, Joseph Keane, Margaret M. Fitzgibbon, Thomas R. Rogers

Summary: The study demonstrates the improved sensitivity of the Ultra compared with the Xpert, particularly in smear negative TB disease, for both pulmonary and extrapulmonary samples in a low TB incidence setting. Cycle threshold (Ct) value for both assays was found to positively correlate with time to TB culture positivity, suggesting that Ct and semiquantitative results could be used as indicators of sample MTBC bacillary burden, and thus, perhaps, of transmission potential. This may have implications for the designation of patient isolation precautions.

MICROBIOLOGY SPECTRUM (2022)

Add to Collection

Article Microbiology

Xpert MTB/RIF Ultra Assay Using Stool: an Effective Solution for Bacilli Identification from Adult Pulmonary Tuberculosis Suspects without Expectorated Sputum

Xia Yu, Fen Wang, Ruyan Ren, Lingling Dong, Yi Xue, Liping Zhao, Junnan Jia, Hairong Huang

Summary: This study evaluated the value of Xpert MTB/RIF Ultra (Xpert-Ultra) in diagnosing adult pulmonary tuberculosis (PTB) using stool samples, and compared it with Xpert MTB/RIF on respiratory tract specimens. The study found that although the yield in stool samples by Xpert-Ultra is lower, it can still be useful in detecting disease in presumptive TB patients who cannot expectorate sputum. Xpert-Ultra testing on stool specimens showed comparable sensitivity with Xpert on respiratory tract specimens, making it a promising strategy to improve PTB diagnosis in patients who cannot produce sputum.

MICROBIOLOGY SPECTRUM (2023)

Add to Collection

Article Microbiology

Retrospective Diagnostic Accuracy Study of Abbott RealTime MTB against Xpert MTB/RIF Ultra and Xpert MTB/RIF for the Diagnosis of Pulmonary Tuberculosis and Susceptibility to Rifampin and Isoniazid Treatment

Patrick Howlett, Pamela Nabeta, Nestan Tukvadze, Samuel G. Schumacher, Claudia M. Denkinger

Summary: High-throughput centralized testing for tuberculosis (TB) and drug resistance is crucial, however, limited comparative data exists. This study compared the performance of Abbott RealTime MTB and RealTime MTB RIF/INH to Xpert MTB/RIF Ultra and Xpert MTB/RIF, with Abbott assays showing lower sensitivity for TB detection but similar performance for resistance detection. The differences in TB detection may be attributed to the use of frozen samples for Abbott testing compared to fresh samples for Xpert. Further studies in compliance with manufacturer's instructions are necessary for a fair comparison.

MICROBIOLOGY SPECTRUM (2021)

Add to Collection

Article Medicine, General & Internal

Optimising Xpert-Ultra and culture testing to reliably measure tuberculosis prevalence in the community: findings from surveys in Zambia and South Africa

Sian Floyd, Eveline Klinkenberg, Petra de Haas, Barry Kosloff, Thomas Gachie, Pete J. Dodd, Maria Ruperez, Chali Wapamesa, Michael J. Burnett, Nico Kalisvaart, Redwaan Vermaak, Tila Mainga, Albertus Schaap, Sarah Fidler, Linda Mureithi, Kwame Shanaube, Richard Hayes, Helen Ayles

Summary: This study aimed to design an accurate diagnostic algorithm for tuberculosis (TB) prevalence surveys (TBPS) that limits the use of culture. Using Xpert-Ultra as the primary diagnostic test and confirming with culture can efficiently identify TB cases and significantly reduce the requirement for culture in surveys.

BMJ OPEN (2022)

Add to Collection

Article Multidisciplinary Sciences

Comparison of tests done, and tuberculosis cases detected by Xpert® MTB/RIF and Xpert® MTB/RIF-Ultra in Uganda

Michael Kakinda, Didas Tugumisirize, Abdunoor Nyombi, Marvin Mugisha, Stavia Turyahabwe, Simon Walusimbi, Joseph K. B. Matovu

Summary: This study found no significant difference in test performance and overall detection of drug-susceptible TB and Rifampicin-resistant TB when using Xpert (R) MTB/RIF Ultra and Xpert (R) MTB/RIF assays.

PLOS ONE (2022)

Add to Collection

Article Infectious Diseases

Detection of Mycobacterium tuberculosis Rifampicin Resistance Conferred by Borderline rpoB Mutations: Xpert MTB/RIF is Superior to Phenotypic Drug Susceptibility Testing

Hui Xia, Yuanyuan Song, Yang Zheng, Shengfen Wang, Bing Zhao, Wencong He, Dongxin Liu, Xichao Ou, Yang Zhou, Yanlin Zhao

Summary: This study compared the ability of molecular assay and phenotypic drug susceptibility tests to detect borderline rifampicin resistance in Mycobacterium tuberculosis. The results showed that the molecular-based Xpert MTB/RIF had a significantly higher detection rate than phenotypic methods. Extending the incubation time or lowering the cutoff value of the MIC method can improve the detection of borderline rifampicin resistance.

INFECTION AND DRUG RESISTANCE (2022)

Add to Collection

Article Microbiology

Rapid Detection of Extensive Drug Resistance by Xpert MTB/XDR Optimizes Therapeutic Decision-Making in Rifampin-Resistant Tuberculosis Patients

Xinchang Chen, Rong Li, Shijia Ge, Yang Li, Cui Cai, Taoping Weng, Yilin Zhang, Jingwen Jiang, Zhen Feng, Yuanyuan Chen, Yungui Zhang, Jian Ma, David H. Persing, Jiazhen Chen, Yi-Wei Tang, Feng Sun, Wenhong Zhang

Summary: The Xpert MTB/XDR assay is crucial for diagnosing tuberculosis and rifampin resistance, but its potential in tailoring treatment regimens and improving outcomes for patients with rifampin-resistant tuberculosis requires further investigation.

JOURNAL OF CLINICAL MICROBIOLOGY (2023)

Add to Collection

Article Respiratory System

Tuberculosis diagnostic accuracy of stool Xpert MTB/RIF and urine AlereLAM in vulnerable children

Patrick Orikiriza, Julianna Smith, Bob Ssekyanzi, Dan Nyehangane, Ivan Mugisha Taremwa, Esther Turyashemererwa, Onesmas Byamukama, Tobias Tusabe, Elisa Ardizzoni, Ben J. Marais, Eric Wobudeya, Elizabeth Kemigisha, Juliet Mwanga-Amumpaire, Dora Nampijja, Maryline Bonnet

Summary: This study evaluates the diagnostic accuracy of stool Xpert MTB/RIF and urine AlereLAM tests in children at high risk for disseminated tuberculosis. The results indicate that while stool Xpert MTB/RIF has excellent specificity, its sensitivity is suboptimal. Urine AlereLAM is compromised by poor sensitivity and specificity in children.

EUROPEAN RESPIRATORY JOURNAL (2022)

Add to Collection

Article Infectious Diseases

Xpert MTB/RIF Ultra assay for the detection of Mycobacterium tuberculosis in people with negative conventional Xpert MTB/RIF but chest imaging suggestive of tuberculosis in Dhaka, Bangladesh

Samanta Biswas, Mohammad Khaja Mafij Uddin, Kishor Kumar Paul, Md Fahim Ather, Shahriar Ahmed, Rumana Nasrin, Senjuti Kabir, Scott K. Heysell, Sayera Banu

Summary: This study suggests that Ultra provides improved detection and accuracy among Xpert-negative patients in a cohort with a high likelihood of pulmonary tuberculosis.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2022)

Add to Collection

Review Infectious Diseases

Use of Xpert MTB/RIF and Xpert Ultra in extrapulmonary tuberculosis

Mirae Park, Onn Min Kon

Summary: Despite advancements in TB diagnostics with Xpert MTB/RIF and Xpert Ultra, there is a need to further optimize their diagnostic yield in EPTB samples. Research is needed to standardize sample preparation and understand the role of these tests in different burden settings. Additionally, the launch of rapid second-line drug resistance PCR and whole genome sequencing may provide a more comprehensive diagnostic approach for tackling the global health burden of TB.

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2021)

Add to Collection

Article Infectious Diseases

Detection of pulmonary tuberculosis in children using the Xpert MTB/RIF Ultra assay on sputum: a multicenter study

Xiaoshan Peng, Qiong Liao, Min Fang, Yu Zhu, Yan Shi, Shuting Quan, Yacui Wang, Li Duan, Xiaomei Shi, Yang Liu, Manzhi Wang, Qingsong Wei, Haiyi Zhou, Yanchun Wang, Xirong Wu, Yao Yao, Lin Sun, Adong Shen, Chaomin Wan

Summary: The study evaluated the utility of Xpert MTB/RIF Ultra in detecting pulmonary tuberculosis in children, showing higher sensitivity and specificity, especially in combination with MTB culture. The results suggest that Xpert MTB/RIF Ultra should be implemented for higher confirmation rates in pediatric pulmonary tuberculosis diagnosis.

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2022)

Add to Collection

Editorial Material Respiratory System

Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment

Sophia B. Georghiou, Timothy C. Rodwell, Alexei Korobitsyn, Said H. Abbadi, Kanchan Ajbani, Jan-Willem Alffenaar, David Alland, Nataly Alvarez, Sonke Andres, Elisa Ardizzoni, Alexandra Aubry, Rossella Baldan, Marie Ballif, Ivan Barilar, Erik C. Bottger, Soumitesh Chakravorty, Pauline M. Claxton, Daniela M. Cirillo, Inaki Comas, Chris Coulter, Claudia M. Denkinger, Brigitta Derendinger, Edward P. Desmond, Jurriaan E. M. de Steenwinkel, Keertan Dheda, Andreas H. Diacon, David L. Dolinger, Kelly E. Dooley, Matthias Egger, Maha R. Farhat, Lanfranco Fattorini, Iris Finci, Laure Fournier Le Ray, Victoria Furio, Ramona Groenheit, Tawanda Gumbo, Scott K. Heysell, Doris Hillemann, Harald Hoffmann, Po-Ren Hsueh, Yi Hu, Hairong Huang, Alamdar Hussain, Farzana Ismail, Kiyohiko Izumi, Tomasz Jagielski, John L. Johnson, Priti Kambli, Kone Kaniga, G. H. R. Eranga Karunaratne, Meenu Kaushal Sharma, Peter M. Keller, Ellis C. Kelly, Margarita Kholina, Mikashmi Kohli, Katharina Kranzer, Ian F. Laurenson, Jason Limberis, S-Y Grace Lin, Yongge Liu, Alexandre Lopez-Gavin, Anna Lyander, Diana Machado, Elena Martinez, Faisal Masood, Satoshi Mitarai, Nomonde R. Mvelase, Stefan Niemann, Vladyslav Nikolayevskyy, Florian P. Maurer, Matthias Merker, Paolo Miotto, Shaheed Omar, Ralf Otto-Knapp, Moises Palaci, Juan Jose Palacios Gutierrez, Sharon J. Peacock, Charles A. Peloquin, Jennifer Perera, Catherine Pierre-Audigier, Suporn Pholwat, James E. Posey, Therdsak Prammananan, Leen Rigouts, Jaime Robledo, Neesha Rockwood, Camilla Rodrigues, Max Salfinger, Marcos C. Schechter, Marva Seifert, Sarah Sengstake, Thomas Shinnick, Natalia Shubladze, Vitali Sintchenko, Frederick Sirgel, Sulochana Somasundaram, Timothy R. Sterling, Andrea Spitaleri, Elizabeth Streicher, Philip Supply, Erik Svensson, Elisa Tagliani, Sabira Tahseen, Akiko Takaki, Grant Theron, Gabriela Torrea, Armand Van Deun, Annelies Van Rie, Dick van Soolingen, Roger Vargas, Amour Venter, Nicolas Veziris, Cristina Villellas, Miguel Viveiros, Robin Warren, Shu'an Wen, Jim Werngren, Robert J. Wilkinson, Caie Yang, Tingting Zhang, Danila Zimenkov, Nazir Ismail, Thomas Schon, Claudio U. Koser, Soudeh Ehsani, Jakko van Ingen, F. Ferda Yilmaz

EUROPEAN RESPIRATORY JOURNAL (2022)

Add to Collection

Article Infectious Diseases

Investigating resistance in clinical Mycobacterium tuberculosis complex isolates with genomic and phenotypic antimicrobial susceptibility testing: a multicentre observational study

Iris Finci, Audrey Albertini, Matthias Merker, Sonke Andres, Nino Bablishvili, Ivan Barilar, Tatiana Caceres, Valeriu Crudu, Eduardo Gotuzzo, Nchimunya Hapeela, Harald Hoffmann, Christine Hoogland, Thomas A. Kohl, Katharina Kranzer, Anna Mantsoki, Florian P. Maurer, Mark P. Nicol, Ecaterina Noroc, Sara Plesnik, Timothy Rodwell, Morten Ruhwald, Theresa Savidge, Max Salfinger, Elizabeth Streicher, Nestani Tukvadze, Robin Warren, Widaad Zemanay, Anna Zurek, Stefan Niemann, Claudia M. Denkinger

Summary: Whole-genome sequencing (WGS) can be used for the diagnosis and management of drug-resistant tuberculosis, and it is correlated with quantitative phenotypic antimicrobial susceptibility testing (AST). The study reveals the potential of WGS for a refined interpretation of resistance and highlights the limitations of our understanding of the genotype and phenotype relationships.

LANCET MICROBE (2022)

Add to Collection

Article Infectious Diseases

Resistance patterns among drug-resistant tuberculosis patients and trends-over-time analysis of national surveillance data in Gabon, Central Africa

Jabar Babatunde Pacome Achimi Agbo Abdul, Bayode Romeo Adegbite, Micheska Epola Dibamba Ndanga, Jean Ronald Edoa, Rhett Chester Mevyann, Guy Rogue Arnault Ibinda Mfoumbi, Tshisekedi Jean de Dieu, Jocelyn Mahoumbou, Christopher Mebiame Biyogho, Sankarganesh Jeyaraj, Stefan Niemann, Bertrand Lell, Peter Gottfried Kremsner, Abraham Sunday Alabi, Ayola Akim Adegnika, Martin Peter Grobusch

Summary: The increasing incidence of MDR-TB infection in Gabon is alarming, especially among individuals aged 25-35. There is a need for improvement in case finding and contact tracing strategies for treatment-naive MDR-TB patients.

INFECTION (2023)

Add to Collection

Letter Public, Environmental & Occupational Health

HIGH-RESOLUTION CHARACTERIZATION OF NOSOCOMIAL MYCOBACTERIUM TUBERCULOSIS TRANSMISSION EVENTS IN BOTSWANA

Jonathan P. Smith, Chawangwa Modongo, John E. Oeltmann, Mbatshi Dima, Ogopotse Matsiri, Othusitse Fane, Tudeutso Molefi, Sanghyuk S. Shin, Ivan Barilar, Stefan Niemann, Nicola M. Zetola, Patrick K. Moonan

AMERICAN JOURNAL OF EPIDEMIOLOGY (2023)

Add to Collection

Letter Infectious Diseases

Pretomanid-resistant tuberculosis

Niklas Koehler, Soenke Andres, Matthias Merker, Viola Dreyer, Agnieszka John, Martin Kuhns, David Krieger, Eva Choong, Nick Verougstraete, Pia Abel zur Wiesch, Sebastian G. Wicha, Christina Koenig, Barbara Kalsdorf, Patricia M. Sanchez Carballo, Dagmar Schaub, Jim Werngren, Thomas Schon, Charles A. Peloquin, Nicolas Schoenfeld, Alain G. Verstraete, Laurent A. Decosterd, Rob Aarnoutse, Stefan Niemann, Florian P. Maurer, Christoph Lange

JOURNAL OF INFECTION (2023)

Add to Collection

Review Infectious Diseases

Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement

Jose Dominguez, Martin J. Boeree, Emmanuelle Cambau, Dumitru Chesov, Francesca Conradie, Vivian Cox, Keertan Dheda, Andrii Dudnyk, Maha R. Farhat, Sebastien Gagneux, Martin P. Grobusch, Matthias Groeschel, Lorenzo Guglielmetti, Irina Kontsevaya, Berit Lange, Frank van Leth, Christian Lienhardt, Anna M. Mandalakas, Florian P. Maurer, Matthias Merker, Paolo Miotto, Barbara Molina-Moya, Florence Morel, Stefan Niemann, Nicolas Veziris, Andrew Whitelaw, Charles R. Horsburgh Jr, Christoph Lange

Summary: Drug-resistant tuberculosis is a global concern and molecular methods provide rapid information on mutations associated with anti-tuberculosis drug resistance. This consensus document, developed by TBnet and RESIST-TB networks, establishes reporting standards for the clinical use of molecular drug susceptibility testing. The panel identified studies linking M tuberculosis mutations with treatment outcomes, and highlights the importance of implementing molecular testing for drug resistance prediction.

LANCET INFECTIOUS DISEASES (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Risk of tuberculosis transmission by children in Hamburg, Germany

Roland Diel, Karen Meywald-Walter, Christian Schwarzbach, Klaas Voss, Viola Dreyer, Stefan Niemann

Summary: A prospective molecular-epidemiologic study in Hamburg, Germany, evaluated the transmission risk of Mycobacterium tuberculosis complex (Mtbc) by children <15 years in a low-incidence setting. The study found that children with pulmonary TB disease, especially those aged below 10 years, rarely transmit Mtbc to their close contacts in a low-incidence setting.

RESPIRATORY MEDICINE (2023)

Add to Collection

Article Microbiology

Wollamide Cyclic Hexapeptides Synergize with Established and New Tuberculosis Antibiotics in Targeting Mycobacterium tuberculosis

Rachel F. Rollo, Giorgia Mori, Timothy A. Hill, Doris Hillemann, Stefan Niemann, Susanne Homolka, David P. Fairlie, Antje Blumenthal

Summary: Shorter and more effective treatment regimens as well as new drugs are urgently needed to reduce the global burden of tuberculosis (TB). This study discovered a new compound called wollamide B1, which has antimycobacterial activity and can synergize with existing TB antibiotics, enhancing their effectiveness. Wollamide B1 also remains effective against drug-resistant TB strains.

MICROBIOLOGY SPECTRUM (2023)

Add to Collection

Article Microbiology

Transmission Dynamics of a Mycobacterium tuberculosis Complex Outbreak in an Indigenous Population in the Colombian Amazon Region

Francy J. Perez-Llanos, Viola Dreyer, Ivan Barilar, Christian Utpatel, Thomas A. Kohl, Martha Isabel Murcia, Susanne Homolka, Matthias Merker, Stefan Niemann

Summary: An outbreak of Mycobacterium tuberculosis complex (MTBC) bacteria was identified among the indigenous populations in the Colombian Amazon region. Whole genome sequencing (WGS) was used to analyze the transmission of MTBC strains and it was found that the use of an alternative reference genome and repetitive regions improved the phylogenetic resolution. The study also revealed the presence of multiple clones in some patients, indicating within-host MTBC diversity.

MICROBIOLOGY SPECTRUM (2023)

Add to Collection

Article Infectious Diseases

Bedaquiline and clofazimine resistance in Mycobacterium tuberculosis: an in-vitro and in-silico data analysis

Lindsay Sonnenkalb, Joshua James Carter, Andrea Spitaleri, Zamin Iqbal, Martin Hunt, Kerri Marie Malone, Christian Utpatel, Daniela Maria Cirillo, Camilla Rodrigues, Kayzad Soli Nilgiriwala, Philip William Fowler, Matthias Merker, Stefan Niemann

Summary: This study identified genetic variations that confer resistance to bedaquiline and clofazimine, and established a mutation catalogue using experimental evolution, protein modelling, genome sequencing, and phenotypic data analysis. The findings advance the understanding of drug resistance mechanisms in Mycobacterium tuberculosis complex strains and provide important genetic testing evidence for the design of effective treatments.

LANCET MICROBE (2023)

Add to Collection

Article Microbiology

Characterization of Two Novel Inhibitors of the Mycobacterium tuberculosis Cytochrome bc1 Complex

Raphael Gries, Michael Dal Molin, Jason Chhen, Edeltraud van Gumpel, Viola Dreyer, Stefan Niemann, Jan Rybniker

Summary: Drug-resistant tuberculosis is a global health care threat that requires new and effective treatment options. Two novel cytochrome bc(1) inhibitors (MJ-22 and B6) have been identified as effective in targeting the Mycobacterium tuberculosis respiratory chain in human macrophages. These compounds have shown low mutation frequencies and unique cross-resistance patterns compared to other advanced cytochrome bc(1) inhibitors.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2023)

Add to Collection

Article Immunology

Limited Nosocomial Transmission of Drug-Resistant Tuberculosis, Moldova

Ecaterina Noroc, Dumitru Chesov, Matthias Merker, Matthias I. Groeschel, Ivan Barilar, Viola Dreyer, Nelly Ciobanu, Maja Reimann, Valeriu Crudu, Christoph Lange

Summary: Using whole-genome sequencing, we aimed to identify transmission events of multidrug-resistant/rifampin-resistant strains of Mycobacterium tuberculosis complex at a tuberculosis hospital in Chisinau, Moldova. Patient information including ward, room, and bed was recorded, and in-hospital transfers were monitored over a period of 1 year. Detailed molecular and patient surveillance revealed only 2 nosocomial transmission events.

EMERGING INFECTIOUS DISEASES (2023)

Add to Collection

Article Multidisciplinary Sciences

Prediction of drug resistance by Sanger sequencing of Mycobacterium tuberculosis complex strains isolated from multidrug resistant tuberculosis suspect patients in Ethiopia

Eyob Abera Mesfin, Matthias Merker, Dereje Beyene, Abreham Tesfaye, Yassir Adam Shuaib, Desalegn Addise, Belay Tessema, Stefan Niemann

Summary: In this study, the performance of a Sanger sequencing approach to predict resistance against anti-tuberculosis drugs was assessed in Ethiopia. The results showed a high agreement between Sanger sequencing and phenotypic drug susceptibility testing, making it a promising complementary measure for routine testing in Ethiopia.

PLOS ONE (2022)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.